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Simultaneous In Vitro Assay of the First Four
Enzymes in the Fungal Aspartate Pathway Identifies
a New Class of Aspartate Kinase Inhibitor
tanoic acid [3] have been shown to target homocysteine
synthase [4], threonine synthase [5], and HSD [6], respec-
tively, and inhibit the growth of fungi (Figure 1). The impor-
tance of this pathway in fungi and other microbes has
resulted in a number of studies to identify and character-
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1200 Main Street ize inhibitors of various component enzymes [7–10].
With this in mind, we sought to identify other com-West Hamilton, Ontario L8N 3Z5
Canada pounds from a chemical library that could inhibit the
fungal aspartate pathway. This could be achieved by
separately screening the library against each enzyme in
the pathway. However, this is costly in terms of theSummary
chemicals themselves, time, substrates, and other ma-
terials. Furthermore, (1) it is not readily possible to screenThe biosynthesis of amino acids derived from Asp
ASD in the metabolically relevant direction as its sub-(Met, Thr, and Ile) is a target for antifungal agents. We
strate, aspartyl-4-phosphate, is unstable, and (2) HSDhave developed a simultaneous in vitro assay of the
uses aspartate-4-semialdehyde, which is not commer-first four enzymes of the fungal aspartate pathway:
cially available and must be chemically synthesized. Toaspartate kinase, aspartate semialdehyde dehydro-
obviate these problems, we designed a pathway assaygenase, homoserine dehydrogenase, and homoserine
whereby the first four enzymes, leading to methionineO-acetyltransferase. This reconstructed pathway assay
biosynthesis, are assayed simultaneously (Figure 2). Suchwas initiated with the readily accessible amino acid
an in vitro pathway assay has the obvious advantages ofL-Asp and thus circumvents the obstacles of substrate
time and cost savings, but also, each additional enzymeavailability and stability for aspartate semialdehyde
screened simultaneously increases the likelihood thatdehydrogenase and homoserine dehydrogenase. The
an inhibitor may be found from a given set of compoundsassay was shown to be suitable for high-throughput
in a single screen [11]. A pathway assay may also main-screening of chemical libraries for the identification
tain protein-protein interactions that occur in vivo, whichof inhibitors of all four component enzymes. A screen
may be important for the function of the enzymes. Suchof a library of 1000 small molecules identified a novel
interactions have been found in the Escherichia coliclass of 7-chloro-4([1,3,4]thiadiazol-2-ylsulfanyl)-quino-
aspartate pathway enzymes aspartate semialdehydeline aspartate kinase inhibitors that have the potential
dehydrogenase and the bifunctional aspartate kinaseto act as leads in the development of new antifungal
I–homoserine dehydrogenase I, which facilitate sub-agents.
strate shuttling of the unstable intermediate aspartyl-4-
phosphate [12]. Finally, the pathway assay also allows
Introduction the identification of compounds, which in principle could
be metabolized by the enzymes in the pathway to new
The fungal aspartate pathway is required for the biosyn- forms that have inhibitory activity [13].
thesis of threonine, isoleucine, and methionine (Figure
1). The first step in this process is activation of aspartate
by phosphorylation catalyzed by aspartate kinase (AK). Results and Discussion
Using NADPH, aspartate semialdehyde dehydrogenase
(ASD) then reduces aspartyl-4-phosphate to aspartate- The first four enzymes of the fungal aspartate pathway
4-semialdehyde. In the next step, homoserine dehydro- were empirically linked together to establish the assay
genase (HSD) catalyzes the reduction of aspartate semi- in progressive steps, starting with Saccharomyces cere-
aldehyde to generate the alcohol homoserine by using visiae AK (AKSc). AKSc was assayed for adenosine diphos-
either NADPH or NADH. Homoserine sits at a junction phate (ADP) production by coupling to pyruvate kinase
in the pathway: phosphorylation by homoserine kinase and lactate dehydrogenase (PK-LDH). Sequential addi-
commits the carbon skeleton to biosynthesis of threo- tions of the S. cerevisiae enzymes ASD (ASDSc) and HSD
nine and isoleucine, whereas acetylation by homoserine (HSDSc), which were both assayed by monitoring NADPH
O-acetyltransferase (HSAT) commits it to methionine oxidation, and Schizosaccharomyces pombe HSAT
biosynthesis. (HSATSp), assayed for CoASH production, were opti-
The pathway is a good target for new antifungal agents mized such that AKSc was rate limiting, and the additional
because it is required for fungal viability and is not found enzymes were present at levels that would sustain rates
in mammals, which is why threonine, isoleucine, and me- just exceeding that set by AKSc. To ensure that these
thionine must be obtained from the mammalian diet. criteria were being met at each optimized step, the
Additionally, the essentiality of the pathway has been steady-state kinetic parameters and the L-Thr IC50 of
chemically validated as the natural products azoxybacil- AKSc were assessed prior to optimizing a subsequent
lin [1], rhizocticin [2], and 2-amino-5-hydroxy-4-oxopen- step (Table 1). With the exception of the ATP Km values,
which varied 5-fold, the remaining parameters for AKSc
were similar after optimizing each step, indicating that*Correspondence: wrightge@mcmaster.ca
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Figure 1. The Fungal Aspartate Pathway Showing the Sites of Action of the Natural Product Inhibitors Azoxybacillin, the Rhizocticins, and
2-amino-5-hydroxy-4-oxopentanoic Acid
AKSc remained rate limiting. To establish the ability of of the pathway assay to identify compounds that inhibit
any of the enzymes present.the pathway assay to respond to inhibitors of AKSc,
HSDSc, and HSATSp, IC50s of known inhibitors of each High-throughput screens must be robust to maximize
the chances of identifying inhibitory compounds andenzyme were determined using the pathway assay (Ta-
ble 1). These include the AK inhibitors L-Thr and -hydro- minimize false positives. One way to visualize the ro-
bustness of the assay is to analyze a significant numberxynorvaline [14], the HSD inhibitor 3-tert-butyl-4-hydro-
xyphenyl sulfide (L. Ejim and G.W., unpublished data), of positive (100% activity) and negative (0% activity)
controls obtained during the screen. The spread of theand the HSAT inhibitor 2,3-dibromomalonamide (I.N.
and G.W., unpublished data). In all cases, IC50s were data values between an arbitrary cutoff of three standard
deviations between both positive and negative controlsfound to be within 2-fold of the values determined in
assays of the individual enzymes, establishing the ability provides a measure of quality of the assay and its use-
Figure 2. The Assay of the First Four Enzymes in the Fungal Aspartate Pathway
Reagents added to the assay mixture are indicated in bold.
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Table 1. Optimization and Inhibition of Enzyme Throughput
ATP Asp
Linked Enzymes Km(mM) kcat(s1) Km(mM) kcat(s1) Inhibitor IC50(mM) Target Enzyme
AKSc-PK-LDH 1.3 40 3.3 36 L-Thr 3.4 AK
AKSc-ASDSc 0.5 49 2.5 36 L-Thr 4.5 AK
AKSc-ASDSc-HSDSc 2.3 50 3.4 43 L-Thr 3.6 AK




Inhibitor controls and AKSc steady-state kinetic parameters for each step in the development of the pathway assay.
fulness in screening, which we term the screening win- to be 0.65, indicating that the screening window can
reliably identify enzyme inhibitors [15].dow (Figure 3A). The statistical parameter Z reports
quantitatively on the data variation and provides a means The results of a screen of the pathway assay in dupli-
cate against a 1000-compound chemical library at aof assessing the quality of the screen. The Z factor (see
Equation 3 in Experimental Procedures) was determined concentration of 10 M are shown graphically (Figure
Figure 3. Evaluation of In Vitro Asp Pathway
Screen
(A) Plot of 100% () and 0% () activity con-
trols for the high-throughput screen. Dashed
lines indicate the average for the controls;
heavy dashed lines indicate three standard
deviations. The screening window is located
between the inner three standard deviation
lines for the 100% and 0% activity controls,
at approximately 0.01 and 0.004 nmol/s, re-
spectively.
(B) Results of the screen of a library of 1000
small molecules against the pathway assay.
Duplicate values for each compound are plot-
ted on opposing axes, if the duplicates are
in agreement they should fall on a line with
a slope of 1 (dashed line). Three standard
deviations below the average result is consid-
ered to be statistically significant inhibition
and is demarked by thick lines.
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Table 3. Identification of the Enzyme Inhibited by Compound 2Table 2. SAR of 7-chloro-4([1,3,4]thiadiazol-2-ylsulfanyl)-
quinoline Aspartate Kinase Inhibitors Identified in the Screen
Linked Enzymes IC50 (M)
Compound IC50(M) AKSc-ASDSc-HSDSc-HSATSp 3.1  0.52
AKSc-ASDSc-HSDSc 12  4.3
AKSc-ASDSc 12  2.5
AKSc-PK-LDH 3.1  0.78
1 18  3.7
way beginning with AKSc, as well as the assay for ADP
production by AKSc (Table 3). Because IC50 values were
obtained from all sequential combinations of the path-
way and the values were within 4-fold of each other,2 3.1 0.8
both compounds were concluded to be AKSc inhibitors.
We investigated the mode of AKSc inhibition and Ki
values for 1 and 2 by using an AKSc-ASDSc coupled assay
to look for NADPH oxidation. Double reciprocal plots
for the inhibition of AKSc by 1 versus both substrates
appeared to be competitive; however, attempts to fit3 3.6 0.8
the data to any standard model of inhibition were uncon-
vincing (data not shown). Furthermore, close structural
analogs of 1 showed no inhibition of AK at concentra-
tions of 30 M, therefore, given this weak activity, we
elected not to pursue further evaluation of this com-
4 1.6 0.7
pound.
On the other hand, compound 2 was found to be a
reversible inhibitor of AKSc. Analysis of the steady-state
inhibition data revealed that 2 fit best to a model of
partial noncompetitive inhibition of ATP (Ki, 3.6  0.22
5 n.i.a M; , 0.31  0.01) and partial mixed inhibition of L-Asp
(Ki, 4.0  0.85 M; , 0.50  0.11; , 0.33  0.02) (Figure
4). These models of inhibition suggest that 2 may be
binding at a site that does not overlap with either sub-
strate and where the enzyme•substrate•inhibitor com-
plex can still produce product but at an impaired rate6 n.i.a
[16]. Compounds 1 and 2 had no effect on the growth
of S. cerevisiae DL1, Candida parapsilosis ATCC 90018,
and Candida albicans ATCC 90028 in minimal RPMIa No inhibition observed at a concentration of 30 M.
liquid media at concentrations up to 64 g/mL. This could
be the result of the M affinity of the compounds or
reflect membrane transport or efflux problems.3B). To assess the reproducibility of the duplicate assay,
a plot of the activity remaining in the presence of each Structural analogs of 2 were identified in an in silico
substructure search of a 50,000-compound chemicalcompound for each duplicate assay was constructed
where the x and y coordinates for each data point are library from Maybridge plc. IC50s were determined using
the AKSc-PK-LDH assay for each analog to determinethe first and second values, respectively, determined for
each compound (Figure 3B). If the duplicates are in what structural features were important for inhibition of
AKSc (Table 2). Two analogs of 2 that maintain the coreperfect agreement they will fall on a line with a slope of
one and a bias in the assay would be indicated by a 7-chloro-4([1,3,4]thiadiazol-2-ylsulfanyl)-quinoline
structure, 3 and 4, showed IC50s similar to the parentnonrandom distribution of the results about this line.
Three standard deviations below the average value was compound, indicating that the 2-phenoxypyridine group
can be replaced by other heterocycles. This portion ofused as the statistically significant cutoff to define a
compound as being an inhibitor of the assay. Using the molecule is important for enzyme affinity as 5, in
which the 2-phenoxypyridine is replaced by an isobu-these criteria, the screen identified two compounds as
reproducible inhibitors from the 1000-compound chemi- tene group, shows no interaction with the enzyme at 30
M, the highest concentration tested (Table 2). Similarly,cal library.
The structures of the compounds identified in the the 4-thio-7-chloroquinoline group was also essential,
as the replacement with a cyclopropane group (com-screen, a thiourea substituted with 2,4-dichlroro-6-(1-
imino-ethyl)-phenol and 3-trifluromethylphenyl groups pound 6) results in loss of activity (Table 2).
(1) and N-[5-(7-chloro-quinolin-4-ylsulfanyl)-[1,3,4]thia-
diazol-2-yl]-2-phenoxy-nicotinamide (2), are shown in Significance
Table 2. To empirically determine which pathway en-
zyme was inhibited by compounds 1 and 2, IC50s were We have designed and optimized a pathway assay of
the first four enzymes in the fungal aspartate pathwaydetermined for all sequential combinations of the path-
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Figure 4. Inhibition of AKSc by Compound 1
Double reciprocal plots for the inhibition of
AKSc by 1.
(A) 1 versus ATP. Concentration of 1:, 0M;
, 2 M; , 5 M; , 9 M; , 15 M; , 25
M.
(B) 1 versus L-Asp. , 0 M; , 0.7 M; ,
2 M;, 7 M. The activity of AKSc was moni-
tored by coupling aspartyl-4-phosphate pro-
duction to ASDSc, as described in Experimen-
tal Procedures.
The HOM2 gene encoding ASDSc was amplified from S. cerevisiaefor use in high-throughput screening of chemical li-
genomic DNA via the polymerase chain reaction with the oligonucle-braries. The aspartate pathway is a good target for
otide primers 5-GGTGGTCATATGGCTGGAAAGAAAATTGCTGG andnew antifungal agents, as it is not found in mammals
5-CCGCTCGAGGGATCCTTAAATCAAGTTTCTTGCTAGTAAGATT
and is required for fungal viability shown by several TCGG. We cloned the amplified fragment into the NdeI and XhoI
natural products, which inhibit the pathway. This work restriction sites by using standard techniques. The resulting DNA
has demonstrated that this pathway assay is amenable sequence-confirmed plasmid, pET28ASDSc, was transformed into
to high-throughput screening, which has several ad- E. coli BL21(DE3) cells allowing expression of ASDSc with an N-ter-
minal hexa-histidine tag.vantages over separately screening each enzyme, in-
The His-tagged enzyme was expressed in E. coli BL21(DE3)/cluding time and cost improvements, but also the
pET28  ASDSc by growing two 1 liter cultures in LB, supplementedability to screen ASDSc and HSDSc in the metabolically
with 50 g/mL kanamycin to an OD600 of 0.6 at 37C. The culturesrelevant direction. This pathway assay enabled the
were cooled in an ice water bath to 16C, isopropyl -D-1-thiogalac-
identification of a new class of inhibitors of fungal topyranoside (IPTG) was added to a final concentration of 1 mM,
AK, and structure activity analysis revealed structural and incubated overnight at 16C in an orbital shaker at 250 rpm.
constraints for inhibition. These are the first reported Cells were harvested by centrifugation at 13,000 	 g for 10 min, the
cell pellet was resuspended in 20 ml of 20 mM 4-(2-hydroxyethyl)pi-non-amino acid inhibitors of fungal AK and as such
perazine-1-ethanesulfonic acid (HEPES) (pH 8.0), and lysed withcould serve as leads in new antifungal compound de-
three passes through a French pressure cell at 10,000 psi in thevelopment.
presence of 1 mM phenylmethylsulfonyl fluoride. Following centrifu-
gation for 10 min at 43,000 	 g, the supernatant was applied on toExperimental Procedures
a 5 ml Ni NTA Agarose column, the column was washed with 20
mM HEPES (pH 8.0) until the OD280 decreased to less than 100 mAu,Cloning, Expression, and Purification of Fungal
and the bound protein was eluted with a gradient of 0–100 mMAspartate Pathway Enzymes
imidazole in 20 mM HEPES (pH 8.0). Active fractions were identifiedCloning, expression, and purification of AKSc and HSDSc are de-
scribed elsewhere [17]. immediately, pooled, and dialyzed overnight against 4 liters of 20
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mM HEPES (pH 8.0). The dialyzed enzyme was concentrated and Assay for CoASH Production
HSATSp production of CoASH was by monitored by in situ titrationfrozen at 80C with 10% glycerol.
We had difficulties producing HSAT from S. cerevisiae in sufficient of 5,5-dithiobis-(2-nitrobenzoic acid) (DTNB) [19]. Production of the
mixed disulfide of CoASH-5-thio-2-nitrobenzoic acid and release ofquantity and quality for these studies and therefore elected to pro-
duce the 66% homologous (50% identical) enzyme from S. pombe. the chromophoric thiolate was monitored at 412 nm (
412 nm  13600
M1cm1) (Figure 2). The assay was buffered with 100 mM HEPESThe MET2 gene encoding HSATSp was amplified from S. pombe
genomic DNA using the oligonucleotide primers 5-GGGAATTCCA (pH 7.0) and contained 40 mM MgSO4, 10 mM KCl, 0.8 mM ATP,
1.2 mM NADPH, and 0.2 mM AcCoA and the optimized amounts ofTATGGAATCTCAATCTCCGATTGAATCAATTGTCTTTAC and 5-CGC
GGATCCAAGCTTTTACCAGGAGGTTATGTCTTCCATTTCTC. The AKSc, ASDSc, HSDSc, and HSATSp. The pathway assay reactions were
initiated by the addition of a mixture of L-Asp and DTNB, such thatamplified fragment was cloned into the NdeI and HindIII restriction
enzyme sites of pET28 by using standard techniques, and the DNA final concentrations were 6 and 0.22 mM, respectively. Zero percent
activity controls were identical in every respect except for the ab-sequence was verified. The resulting plasmid, pET28 HSATSp, was
transformed into E. coli BL21(DE3) cells allowing the expression of sence of L-Asp. Assays were monitored at 412 nm for a minimum
of 5 min at 30C. Similar assays were used for the purification ofHSATSp with an N-terminal hexa-histidine tag.
The His-tagged enzyme was expressed in E. coli BL21(DE3)/ HSATSp except reactions were initiated with L-homoserine and
DTNB, avoiding the need for the other pathway enzymes and theirpET28  HSATSp in 1 liter of LB supplemented with 50 g/mL kana-
mycin to an OD600 of 0.6 at 37C. The cultures were cooled in an ice substrates.
water bath to 16C, IPTG was added to a final concentration of 1
mM, and were incubated for 2 hr at 16C in an orbital shaker. The Optimization of the Pathway Assay
cultures were harvested by centrifugation at 13,000 	 g for 10 min, The amount of AKSc yielding an easily measured progress curve
and the cells from four 1L cultures resuspended in 30 ml of 20 mM (slope approximately 20–30 times above background) that was linear
HEPES (pH 8.0), and lysed with three passes through a French for at least 5 min was determined by titrating AKSc and assaying for
pressure cell at 10,000 psi. Cell debris was pelleted at 43,000 	 g ADP production. The amount of ASDSc sufficient to just exceed
for 10 min and the supernatant was loaded on a 15 ml Ni NTA the rate established by AKSc was determined empirically by varying
Agarose column. The column was washed until the OD280 decreased ASDSc while keeping AKSc constant and assaying for NADPH oxida-
to less than 100 mAu, and the bound HSATSp was eluted with 10 ml tion. The amount of HSDSc was optimized in a similar manner as for
of 100 mM imidazole in 20 mM HEPES (pH 8.0) directly onto a 20 ml ASDSc; however, the observed slope was twice that found for ASDSc,
Q Sepharose column, which was washed similarly and eluted with because the stoichiometry of NADPH consumption had doubled
a gradient of 0–400 mM NaCl in 20 mM HEPES (pH 8.0). HSATSp active due to the added dehydrogenase activity of HSDSc. To reduce ex-
fractions were pooled and found to yield 20 mg of pure HSATSp. pense, the concentration of NADPH was kept to a minimum, 1.2 mM,
without becoming rate limiting. The amount of HSATSp was optimized
in a similar manner using the assay for CoASH production. ObservedADP Production Assay
activity was found to decrease with increasing concentrations ofAKSc activity was determined by coupling production of ADP with
DTNB, likely due to inactivation of one of the pathway enzymes bythe lactate dehydrogenase-dependent oxidation of reduced NADH
DTNB, therefore this reporter molecule was added at a concentra-in the presence of phosphoenol pyruvate and pyruvate kinase. Reac-
tion just exceeding the limiting substrate concentration with thetion mixtures contained 7 mM ATP, 0.33 U pyruvate kinase, 0.66 U
initiating substrate L-Asp. After each additional enzyme was opti-lactate dehydrogenase, 2.5 mM phosphoenol pyruvate, 1 mM NADH,
mally linked, the AKSc steady-state kinetic parameters along with10 mM KCl, 40 mM MgSO4, 100 mM HEPES (pH 7.5) in a final volume
the L-Thr IC50 were determined to confirm that the rate-limiting stepof 100 l contained in a 96 well flat bottom microtitre plate. A 6 min
remained AKSc.preincubation was used to ensure that any contaminating ADP was
regenerated to ATP as well as allowing for temperature equilibration
Enzyme Screeningto 30C. The reactions were initiated with the addition of at least 25
Compounds from the Maybridge collection were dissolved at 200mM L-aspartate and monitored at 340 nm in a Molecular Devices
M in dimethyl sulfoxide in 96 well microtitre plates. Compounds,Spectramax microtitre platereader. For steady-state kinetics, one
sufficient for a 10 M final concentration, and master mix containingsubstrate was held fixed while the other was varied at eight substrate
buffer, Mg2, enzymes, and substrates were transferred to the assayconcentrations in duplicate, ranging from 0.4 to 7 mM for ATP and
plate and preincubated 15 min at 30C in concentrations identical0.5 to 30 mM L-Asp. Data were fit to Equation 1 for Michaelis-
to the assay conditions for CoASH production. Reactions were initi-Menten kinetics using the computer program GraFit [18].
ated by the addition of a mixture of L-Asp and DTNB, such that




(1) monitored at 412 nm for 5 min at 30C.
The identity of compounds 1 and 2 derived from the screen was
verified by liquid chromatography with mass spectrometry detection.
L-Threonine IC50 Determinations Data Analysis and Characterization of Inhibitory Compounds
Assays were similar to assays for ADP production, with the addition The quantitative measure of the quality of the assay, called the
of L-threonine concentrations ranging from 0.05 to 150 mM; ATP Z factor, was calculated for the assay (Equation 3 [15]).
and L-Asp were present at 5 and 12.5 mM, respectively. Data were
fit to the four-parameter Equation 2, using GraFit [18] to solve for the
Z factor  1   3high  3low(averagehigh  averagelow) (3)IC50, where A  minimum response plateau, D  maximum response
plateau, I  concentration of inhibitor, and S  slope factor.




1   IIC50
S  D (2) The mode of inhibition of AKSc, Ki value, and reversibility of inhibi-
tion by hits derived from the primary screen was determined. To
assess the mode of inhibition, double reciprocal plots were gener-
ated with individual lines fit to a simple double reciprocal model,
Equation 4, and the type of inhibition confirmed by F test comparing
global fits of the data to various models of inhibition, includingNADPH Oxidation Assay
NADPH oxidation by ASDSc separately or with HSDSc was monitored hyperbolic noncompetitive (Equation 5) and hyperbolic mixed inhibi-
tion, (Equation 6). Inhibition constants were obtained from the globalat 340 nm (
340 nm  6300 M1cm1). Conditions for this assay are
identical to those for ADP production with the substitution of ASDSc fit to the appropriate model, using the enzyme kinetics module of
Sigma Plot [20]. Reversibility of inhibition was determined by com-alone or in combination with HSDSc for PK-LDH.
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paring activity of AKSc plus an inhibitor concentration providing 50% 8. Cox, R.J., Gibson, J.S., and Mayo Martin, M.B. (2002). Aspartyl
phosphonates and phosphoramidates: the first synthetic inhibi-inhibition to an AKSc control at 50% of the uninhibited activity follow-
ing 6 min incubation at 30C, diluting to various volumes, and starting tors of bacterial aspartate-semialdehyde dehydrogenase.
Chembiochem. 3, 874–886.the reaction with the same concentrations of all other components
in the ADP production assay. 9. Kish, M.M., and Viola, R.E. (1999). Oxyanion specificity of As-
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dehydrogenase from Saccharomyces cerevisiae: kinetic mech-
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